Atopic Dermatitis: Diagnosis and Treatment

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Atopic dermatitis (AD), or atopic eczema, is a prevalent chronic inflammatory skin disease characterized by intense pruritus and lesions.
• It arises from a complex interplay of immune dysregulation, epidermal gene mutations, and environmental triggers, disrupting skin barrier function.
• The itch-scratch cycle significantly impairs patients' quality of life.

Purpose of the Study:

• To outline the diagnostic criteria for atopic dermatitis.
• To review current and emerging treatment strategies for atopic dermatitis.
• To evaluate the efficacy and limitations of various therapeutic options.

Main Methods:

• Diagnostic criteria established by the American Academy of Dermatology based on symptoms and physical examination.
• Review of maintenance therapies including emollients and daily bathing.
• Analysis of first-line treatments such as topical corticosteroids and topical calcineurin inhibitors (pimecrolimus, tacrolimus).
• Evaluation of ultraviolet phototherapy for moderate to severe cases.
• Assessment of treatments for secondary infections and the inefficacy of oral antihistamines.
• Consideration of newer FDA-approved medications (crisaborole, dupilumab) and their cost implications.

Main Results:

• Topical corticosteroids are first-line for flare-ups; topical calcineurin inhibitors can be adjuncts.
• Ultraviolet phototherapy offers a safe, effective option for moderate to severe AD.
• Antistaphylococcal antibiotics address secondary infections.
• Oral antihistamines are ineffective for pruritus relief.
• Newer agents like crisaborole and dupilumab show efficacy but face cost barriers.

Conclusions:

• Atopic dermatitis management involves a multi-faceted approach combining skincare, topical therapies, and other modalities.
• While newer treatments offer promise, accessibility remains a challenge.
• Further research into cost-effective and evidence-based integrative medicine for AD is warranted.